Cardiotoxicities of Novel Therapies in Hematological Malignancies: Monoclonal Antibodies and Enzyme Inhibitors-Reference-Cited by-同舟云学术

Cardiotoxicities of Novel Therapies in Hematological Malignancies: Monoclonal Antibodies and Enzyme Inhibitors

Published:2023-08 Issue:8 Volume:48 Page:101757
ISSN:0146-2806
Container-title:Current Problems in Cardiology
language:en
Short-container-title:Current Problems in Cardiology

Author:

Prathivadhi-Bhayankaram Sruti,Abbasi Muhannad Aboud,Ismayl Mahmoud,Marar Rosalyn I.,Al-Abcha Abdullah,El-Am Edward,Ahmad Ali,Acevedo Andres Daryanani,Ellauzi Rama,Villarraga Hector,Paludo Jonas,Anavekar Nandan

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference74 articles.

1. Monoclonal antibodies in acute lymphoblastic leukemia;Jabbour;Am Soc Hematol,2015

2. A review of cancer immunotherapy toxicity;Kennedy;CA Cancer J Clin,2020

3. Heart failure therapies for the prevention of her2-monoclonal antibody-mediated cardiotoxicity: a systematic review and meta-analysis of randomized trials;Brown;Cancers (Basel),2021

4. Adverse cardiac events to monoclonal antibodies used for cancer therapy: the risk of Kounis syndrome;Kounis;Oncoimmunology,2014

5. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS);Lyon;Eur Heart J,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiotoxicity Risk of Cancer Treatment in Patients With Underlying Cardiomyopathies: Is Hypertrophic Cardiomyopathy Any Different?;Mayo Clinic Proceedings;2024-02